Abstract
Background Households are a major setting for SARS-CoV-2 infections, but there remains a lack of knowledge regarding the dynamics of viral transmission, particularly in the setting of widespread pre-existing SARS-CoV-2 immunity and evolving variants.
Methods We conducted a prospective, case-ascertained household transmission study in the greater Boston area in March-July 2022. Anterior nasal swabs, along with clinical and demographic data, were collected for 14 days. Nasal swabs were tested for SARS-CoV-2 by PCR. Whole genome sequencing was performed on high-titer samples.
Results We enrolled 33 households in a primary analysis set, with a median age of participants of 25 years old (range 2-66); 98% of whom had received at least 2 doses of a COVID-19 vaccine. 58% of households had a secondary case during follow up and the secondary attack rate (SAR) for contacts infected was 39%. We further examined a strict analysis set of 21 households that had only 1 PCR+ case at baseline, finding an SAR of 22.5%. Genomic epidemiology further determined that there were multiple sources of infection for household contacts, including the index case and outside introductions. When limiting estimates to only highly probable transmissions given epidemiologic and genomic data, the SAR was 18.4%.
Conclusions Household contacts of a person newly diagnosed with COVID-19 are at high risk for SARS-CoV-2 infection in the following 2 weeks. This is, however, not only due to infection from the household index case, but also because the presence of an infected household member implies increased SARS-CoV-2 community transmission. Further studies to understand and mitigate household transmission are needed.
Key Points When community transmission of SARS-CoV-2 is high, distinguishing household transmissions from independent introductions is difficult with either epidemiologic or genomic data alone. Here, we conducted daily nasal sampling with genomic sequencing to understand the dynamics of viral transmission within households.
Competing Interest Statement
P.C.S. is a co-founder of, shareholder in, and scientific advisor to Sherlock Biosciences, Inc and Delve Bio; she is also a Board member of and shareholder in Danaher Corporation. P.C.S. has filed IP related to genome sequencing and analysis. The authors declare no other conflicts of interests.
Funding Statement
This study was supported by the Massachusetts Consortium for Pathogen Readiness (K.E.S.), Beth Israel Deaconess Medical Center (K.E.S.), National Institutes of Health (R01-GM120122 to M.S.), Harvard Catalyst, the National Institute of General Medical Sciences (T32GM007753 and T32GM144273 to B.A.P.), the Centers for Disease Control and Prevention (CDC) COVID-19 baseline genomic surveillance contract to the Clinical Research Sequencing Platform (75D30121C10501 to B.L.M.), a CDC Broad Agency Announcement (75D30120C09605 to B.L.M.), the CDC Pathogen Genomic Centers of Excellence (NU50CK000629 to B.L.M and P.C.S), the National Institute of Allergy and Infectious Diseases (U19AI110818 and U01AI151812 to P.C.S.), and Howard Hughes Medical Institute (P.C.S.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The BIDMC Committee on Clinical Investigation, its Institutional Review Board (IRB), approved the study protocol (#2022P000021). Consent procedures were completed via phone/video conferencing or in-person. All enrolled participants provided verbal informed consent. Participants who met applicable IRB guidelines for provision of assent underwent an age-appropriate assent process; informed consent for study participation was obtained from each participant's parent or legal guardian before any study-specific procedures were performed. Sequencing of SARS-CoV-2-positive specimens was covered under protocol #1612793224, reviewed and approved by the Massachusetts Institute of Technology (MIT) IRB.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
There was no change to the manuscript. An error in the author list as viewable on medrxiv was corrected.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
